Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Verhamme

Showing results (121-130 of 359) with videos related to

Pageof 36
Sort By:
Thrombosis Research|February 25, 2015
Duration of anticoagulation after venous thromboembolism in real world clinical practiceWalter Ageno, Angel Samperiz, Ruth Caballero, et al.
Cardiovascular Research|July 10, 2015
Platelet endothelial aggregation receptor-1: a novel modifier of neoangiogenesisChristophe Vandenbriele, Alexandre Kauskot, Ine Vandersmissen, et al.
British Journal of Clinical Pharmacology|December 16, 2021
Improving appropriate use of anticoagulants in hospitalised patients: A pharmacist-led Check of Medication Appropriateness interventionCharlotte Quintens, Peter Verhamme, Thomas Vanassche, et al.
Presse Medicale (Paris, France : 1983)|November 9, 2015
Pulmonary embolism: Epidemiology and registriesManuel Monreal, Isabelle Mahé, Alessandra Bura-Riviere, et al.
European Heart Journal|June 11, 2016
Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summaryHein Heidbuchel, Peter Verhamme, Marco Alings, et al.
The New England Journal of Medicine|December 9, 2014
Factor XI antisense oligonucleotide for prevention of venous thrombosisHarry R Büller, Claudette Bethune, Sanjay Bhanot, et al.
Journal of Thrombosis and Thrombolysis|January 18, 2023
Risk of venous thromboembolic events after COVID-19 infection: a systematic review and meta-analysisMarco Zuin, Stefano Barco, George Giannakoulas, et al.
Acta Chirurgica Belgica|September 26, 2024
Pericardial fenestration and thoracic duct ligation for treatment of chylopericardium as first symptom of underlying generalized lymphatic anomaly: a case reportRoza S Makarian, Oana Mirea, Peter Verhamme, et al.
Thrombosis and Haemostasis|April 26, 2013
Single-dose TB-402 or rivaroxaban for the prevention of venous thromboembolism after total hip replacement. A randomised, controlled trialPeter Verhamme, Sophie Gunn, Elisabeth Sonesson, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|September 2, 2015
Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillationHein Heidbuchel, Peter Verhamme, Marco Alings, et al.
Pageof 36

Showing results (121-130 of 359) with videos related to

Sort By:
Pageof 36
Thrombosis Research|February 25, 2015
Duration of anticoagulation after venous thromboembolism in real world clinical practiceWalter Ageno, Angel Samperiz, Ruth Caballero, et al.
Cardiovascular Research|July 10, 2015
Platelet endothelial aggregation receptor-1: a novel modifier of neoangiogenesisChristophe Vandenbriele, Alexandre Kauskot, Ine Vandersmissen, et al.
British Journal of Clinical Pharmacology|December 16, 2021
Improving appropriate use of anticoagulants in hospitalised patients: A pharmacist-led Check of Medication Appropriateness interventionCharlotte Quintens, Peter Verhamme, Thomas Vanassche, et al.
Presse Medicale (Paris, France : 1983)|November 9, 2015
Pulmonary embolism: Epidemiology and registriesManuel Monreal, Isabelle Mahé, Alessandra Bura-Riviere, et al.
European Heart Journal|June 11, 2016
Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summaryHein Heidbuchel, Peter Verhamme, Marco Alings, et al.
The New England Journal of Medicine|December 9, 2014
Factor XI antisense oligonucleotide for prevention of venous thrombosisHarry R Büller, Claudette Bethune, Sanjay Bhanot, et al.
Journal of Thrombosis and Thrombolysis|January 18, 2023
Risk of venous thromboembolic events after COVID-19 infection: a systematic review and meta-analysisMarco Zuin, Stefano Barco, George Giannakoulas, et al.
Acta Chirurgica Belgica|September 26, 2024
Pericardial fenestration and thoracic duct ligation for treatment of chylopericardium as first symptom of underlying generalized lymphatic anomaly: a case reportRoza S Makarian, Oana Mirea, Peter Verhamme, et al.
Thrombosis and Haemostasis|April 26, 2013
Single-dose TB-402 or rivaroxaban for the prevention of venous thromboembolism after total hip replacement. A randomised, controlled trialPeter Verhamme, Sophie Gunn, Elisabeth Sonesson, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|September 2, 2015
Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillationHein Heidbuchel, Peter Verhamme, Marco Alings, et al.
Pageof 36